Table 1 Input data used in the model
From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
Cohort | |||
|---|---|---|---|
RSV-prophylaxis | No Prophylaxis | Source | |
Palivizumab as RSV-prophylaxis | |||
Dose | 15 mg/kg | ||
Price | 8.25 EUR/mg | ||
Weight (cost per injection): | |||
1st injection | 5 kg (619 EUR) | ||
2nd injection | 5.4 kg (668 EUR) | ||
3rd injection | 5.8 kg (718 EUR) | ||
4th injection | 6.4 kg (792 EUR) | ||
5th injection | 7 kg (866 EUR) | ||
Total prophylaxis costs per treated infant: | 3664 EUR | ||
RSV-hospitalization | |||
Annual risk of RSV-hospitalization (1st year of life) | 5.34% (RR = 0.55) | 9.70% | Feltes et al. [13] |
Risk of death during RSV-hospitalization | 3.72% | 3.72% | Feltes et al. [13] |
Mean length of stay, RSV-hospitalization | 10.8 days | 13.3 days | Feltes et al. [13] |
Mean length of stay, ICU | 3.0 days | 7.3 days | Feltes et al. [13] |
Mean length of... | |||
supplemental oxygen | 5.2 days | 10.4 days | Feltes et al. [13] |
mechanical ventilation | 1.2 days | 5.6 days | Feltes et al. [13] |
ECMO | 8.2 days | 8.2 days | Khan et al. [27] |
CPAP | 3.5 days | 3.5 days | Greenough et al. [32] |
Cost per day | |||
RSV-hospitalization | 1197 EUR | 1197 EUR | SSVR County Council Price List [33] |
ICU | 1802 EUR | 1802 EUR | SSVR County Council Price List1 [33] |
Supplemental oxygen | 344 EUR | 344 EUR | SÖSVR County Council Price List [34] |
Mechanical ventilation | 344 EUR | 344 EUR | SÖSVR County Council Price List [34] |
ECMO | 8592 EUR | 8592 EUR | SSVR County Council Price List [33] |
CPAP | 3338 EUR | 3338 EUR | SÖSVR County Council Price Lista [34] |
Hotel (1 parent) | 96 EUR | 96 EUR | SSVR County Council Price List [33] |
Productivity loss (1 parent) | 118 EUR | 118 EUR | Statistics Sweden [35] |
Resulting total costs per RSV-hospitalization | 96,918 EUR | 106,344 EUR | |
CHD-associated complications | |||
Risk of delayed surgery, if RSV-hospitalized | 30% | 30% | Granbom et al. [36] |
For infants with delayed surgery: Risk of … | |||
general complication | 40% | 40% | Assumed |
death (during first year) | 1% | 1% | Assumed |
Annual cost of general heart complication | 21,506 EUR | 21,506 EUR | Assumed |
Asthma | |||
Annual risk of asthma | (Depending on age and history of RSV-hospitalization) | ||
Annual cost of asthma | 1440 EUR | 1440 EUR | Neovious et al. [23] |
Utilities | |||
Base utility | 0.89 | 0.89 | Greenough et al. [37] |
Utility decrement of RSV hospitalization | 0.10 | 0.10 | Assumed |
Utility of asthma | 0.79 | 0.79 | Chiou et al. [38] |
Utility decrement of heart complication | 0.10 | 0.10 | Assumed |
Discount rates | |||
Costs (annual) | 3.0% | 3.0% | TLV guidelines [39] |
QALYs (annual) | 3.0% | 3.0% | TLV guidelines [39] |